Nelarabine

From Wikipedia, the free encyclopedia

Nelarabine
Systematic (IUPAC) name
(2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-
5-(hydroxymethyl)oxolane-3,4-diol
Identifiers
CAS number 121032-29-9
ATC code L01BB07
PubChem 3011155
Chemical data
Formula C11H15N5O5 
Mol. mass 297.268 g/mol
Pharmacokinetic data
Bioavailability n/a
Protein binding <25%
Metabolism By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Half life 30 minutes (nelarabine)
3 hours (ara-G)
Excretion Renal
Therapeutic considerations
Licence data

EUUS

Pregnancy cat.

D(US)

Legal status

-only(US)

Routes Intravenous

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. It was later approved in the European Union on August 22, 2007. Complete responses have been achieved with this medication.

It is marketed in the US as Arranon and as Atriance in the EU by GlaxoSmithKline.

[edit] External links